Hepatitis B and Liver Cancer

Our work uses diverse research methods to identify the enablers and barriers to eliminating hepatitis B and liver cancer worldwide.

Group Heads

About

Hepatitis B infection is a global killer. Without treatment, two people die every minute from liver failure and liver cancer. Primary liver cancer is fast growing and the third commonest cause of cancer death worldwide. Our work aims to achieve hepatitis B and liver cancer elimination worldwide.

Our work combines three strategic research pillars:

prevent mother to child hepatitis B transmission and improved vaccination coverage

improve hepatitis B testing, linkage to care and treatment uptake to achieve WHO 2030 hepatitis B elimination targets

increase prevention and early diagnosis of primary liver cancer.

Our team has expertise in mathematical modelling, novel diagnostics development, epidemiology, health systems intervention trials and qualitative methods.

In addition, to achieve maximal clinical impact, our hepatitis B and liver cancer research programs leverage our unique cross-centre partnership with St Vincent’s Hospital, the University of Melbourne and global collaborations.

Current projects

View 5 more

Concurrent liver diseases in liver transplant recipients in Australia

We describe the prevalence and clinical impact of concurrent liver diseases among people undergoing liver transplantation for liver cirrhosis and liver cancer in Australia and New Zealand

Open to students

Public health interventions to achieve hepatitis B elimination and reduce liver cancer

Open to students

Barriers to hepatocellular carcinoma screening uptake

Exploring barriers to HCC screening adherence and attendance.

View 5 more

Past projects

View 2 more

Modelling for evidence-based national hepatitis B testing plans

This project assessed the approach of providing hepatitis B tests to potential new migrants from endemic countries.

Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B

We're identifying the elements of effective clinical management for hepatitis B.

Identifying the structural enablers to the clinical management of people with hepatitis B in general practice: a qualitative investigation

General Practice and other primary health care services are recognised as essential in reducing hepatitis B-related mortality in Australia.

View 2 more

News and features

NHMRC grants for Burnet hepatitis B and STI research

Burnet projects aimed at reducing the burden of hepatitis B in Australia and STIs will be supported by NHMRC Investigator Grants.

Burnet modelling reveals global economic burden of hepatitis B

New Burnet Institute modelling has revealed the significant cost of hepatitis B deaths globally and emphasises the under appreciated economic burden of hepatitis B.